法舒地尔联合西地那非治疗肺动脉高压大鼠疗效观察

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (3): 281-286.

法舒地尔联合西地那非治疗肺动脉高压大鼠疗效观察

徐静 ¹，金晓洁²

¹乐清市第二人民医院呼吸内科，乐清 325608，浙江；² 温州市中心医院呼吸内科，温州 325000，浙江

收稿日期:2016-12-13 修回日期:2017-02-17 出版日期:2017-03-26 发布日期:2017-03-29
作者简介:徐静，女，本科，主治医师，主要从事呼吸内科方向研究。 Tel：15858992551 E-mail：xujing4000@126.com

Effect of fasudil combined with sildenafil in the treatment of pulmonary hypertension in rats

XU Jing ¹, JIN Xiaojie ²

¹ Department of Respiratory Medicine, Second People's Hospital of Yueqing City, Yueqing 325608, Zhejiang, China; ²Department of Respiratory Medicine, Central Hospital of Wenzhou, Wenzhou 325000, Zhejiang, China

Received:2016-12-13 Revised:2017-02-17 Online:2017-03-26 Published:2017-03-29

摘要/Abstract

摘要：

目的:探讨法舒地尔联合西地那非治疗肺动脉高压大鼠的疗效。方法: 将100只大鼠随机分成A、B、C、D和E组，其中A组为空白对照组，B组为肺动脉高压模型组，C组在建模基础上给予法舒地尔治疗，D组在建模基础上给予西地那非治疗，E组在建模基础上给予法舒地尔联合西地那非治疗，比较5组大鼠的血压指标、右心室功能、右心室肥大以及微血管重建情况。结果: C组、D组和E组大鼠右心室收缩压（RVSP）均显著低于B组大鼠，E组大鼠RVSP显著低于C组大鼠（P<0.05）；E组大鼠右心室舒张末期直径（RVEDD）和右心室收缩末期直径（RVESD）显著低于C组大鼠，D组和E组大鼠右心室缩短分数显著高于B组大鼠（P<0.05）；E组大鼠右心室肥大指数（RVH）和右心室比体质量（RV/BW）显著低于C组和D组大鼠（P<0.05）；E组大鼠肺动脉内膜增厚率显著低于B组、C组和D组大鼠（P<0.05），E组大鼠肺动脉ρ激酶活性显著低于B组、C组和D组大鼠（P<0.05）。结论:法舒地尔联合西地那非治疗能够显著改善肺动脉高压大鼠血流动力学指标以及右心室功能，缓解右心室肥大，有利于微血管重建，二者在调控ρ激酶活性，治疗肺动脉过程中可能存在协调作用。

关键词: 法舒地尔, 西地那非, 肺动脉高压

Abstract:

AIM: To investigate the curative effect of fasudil combined with sildenafil in the treatment of pulmonary hypertension in rats. METHODS: 100 rats were randomly divided into A, B, C, D and E group.Group A was control group, group B was set for the model of pulmonary hypertension, group C was given fasudil treatment on the basis of modeling. Group D received sildenafil treatment on the basis of modeling, group E was given fasudil combined with sildenafil treatment on the basis of modeling. The blood pressure, right ventricular function, right ventricular hypertrophy and vascular reconstruction were compared between the 5 groups. RESULTS:The RVSP of C group, D group and E group were significantly lower than that of B group；the RVSP of E group was significantly lower than that of rats in the C group (P<0.05); RVEDD and RVESD of group E were significantly lower than those in the C group, and right ventricular fractional shortening of D group and E group were significantly higher than that in the B group (P<0.05); RV/LV+S and RV/BW of the rats in group E were significantly lower than that of C group and group D (P<0.05); pulmonary artery intimal thickening in rats of group E was significantly lower than that of B group, C group and D group (P<0.05).Rho kinase activity in pulmonary artery of E group was significantly lower than that of B group, C group and D group (P<0.05). CONCLUSION: Fasudil combined with sildenafil treatment can significantly improve the hemodynamics of rats with pulmonary hypertension and right ventricular function as well as relieve right ventricular hypertrophy.It is beneficial to microvascular reconstruction, and there is a cooperative relationship between the two drugs in the regulation of Rho kinase activity and the treatment of pulmonary artery.

Key words: fasudil, sildenafil, pulmonary hypertension

中图分类号:

R965.2

徐静，金晓洁. 法舒地尔联合西地那非治疗肺动脉高压大鼠疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(3): 281-286.

XU Jing, JIN Xiaojie. Effect of fasudil combined with sildenafil in the treatment of pulmonary hypertension in rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 281-286.

参考文献

［1］朱兴旺, 朱小冰. 吸入一氧化氮治疗新生儿持续性肺动脉高压研究进展［J］. 中国新生儿科杂志, 2015, 30(3): 236-240.
［2］Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction : a community-based study ［J］. J Am Col Cardiol, 2014, 7(2): 1047-1052.
［3］黄颖, 蓝登科, 张熹煜, 等. 从痰瘀论治慢性阻塞性肺疾病急性加重期并呼吸衰竭［J］. 长春中医药大学学报, 2016, 32(4): 742-744.
［4］Satoh K, Fukumoto Y, Sugimura K, et al. Plasma cyclophilin A is a novel biomarker for coronary artery disease［J］. Circul J Offic J Jpn Circul Soc, 2012, 77(2): 447-455.
［5］周永清. 黄芪注射液对慢性阻塞性肺疾病加重期患者细胞因子及肺功能的影响［J］. 长春中医药大学学报, 2016, 32(2):337-338.
［6］高汉华, 刘映峰, 钟华英, 等. 川芎嗪联合西地那非对原发性肺动脉高压导致右心室重塑的影响［J］. 中国老年学, 2014,34(9):2383-2385.
［7］Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension［J］. Circul J Offic J Jpn Circul Soc, 2011, 75(8):1801-1810.
［8］Voelkel NF, Gomez-Arroyo J, Abbate A, et al. Pathobiology of pulmonary arterial hypertension and right ventricular failure ［J］. Euro Res J, 2012, 40(6): 1555-1565.
［9］Aguero J, Ishikawa K, Hadri L, et al. Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model ［J］. J Am Col Cardiol, 2016, 67(17): 2032.
［10］Lewis GD, Ngo D, Hemnes AR, et al. Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension.［J］. J Am Col Cardiol, 2016, 67(2): 174-189.
［11］Shimokawa H. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension; a pilot efficacy trial ［J］. Circul J Offic J Jpn Circul Soc, 2013, 77(10): 2619-2625.
［12］Liu AJ, Ling F, Wang D, et al. Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip1 via the ERK signal pathway［J］. Chin Med J, 2011, 125(19): 3098-3104.
［13］Lewis GD, Ngo D, Hemnes AR, et al. Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension ［J］. J Am Col Cardiol, 2016, 67(2): 174-189.
［14］Sliwa K, van Hagen IM, Budts W, et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology ［J］. Euro J Heart Fail, 2016, 18(9): 1119-1128.
［15］Bertero T, Lu Y, Annis S, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension ［J］. J Clin Invest, 2014, 124(8): 3514-3528.

[1]	沈畅, 艾可龙, 胡长平. 低氧诱导因子1信号通路调控低氧性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 114-120.
[2]	孟时, 王中群. 人类免疫缺陷病毒相关性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1431-1440.
[3]	王睿, 潘进进, 李华, 袁予辉. 褪黑素调节肺动脉高压的作用与机制研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 444-448.
[4]	胡晓燕, 徐秋萍. 左西孟旦在心脏外科术后重症患者的应用研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1027-1032.
[5]	王超，格根图雅，徐磊. 硼替佐米治疗肺动脉高压的作用机制[J]. 中国临床药理学与治疗学, 2019, 24(8): 957-960.
[6]	陈娟燕，宋水江，徐冬娟，徐琼，李鸿飞. 法舒地尔联合瑞舒伐他汀治疗血管性痴呆对认知功能、C-反应蛋白及氧化应激的影响[J]. 中国临床药理学与治疗学, 2018, 23(10): 1153-1158.
[7]	黄友明, 王安才, 查日田. 舒利迭联合茶碱对慢性阻塞性肺疾病稳定期患者肺动脉压及右心功能的观察[J]. 中国临床药理学与治疗学, 2014, 19(8): 920-925.
[8]	武彩霞, 杜冠华. 肺血管内皮损伤与肺动脉高压[J]. 中国临床药理学与治疗学, 2012, 17(4): 463-471.
[9]	唐兰兰, 王淑君, 黎关龙, 王园园, 周俊辉, 赵珊, 刘亚坤, 王万铁. 三七皂苷单体R₁对低氧高二氧化碳肺动脉平滑肌细胞ERK1/2表达的影响[J]. 中国临床药理学与治疗学, 2011, 16(11): 1216-1221.
[10]	邓晓兰, 谭志荣, 陈尧, 李慧, 王医成, 黄琪, 欧阳冬生. LC-MS/MS内标法测定人血浆中西地那非的浓度[J]. 中国临床药理学与治疗学, 2011, 16(11): 1272-1276.
[11]	肖雄, 侯颖, 李小强. 5-羟色胺受体拮抗剂在肺动脉高压防治中的应用与展望[J]. 中国临床药理学与治疗学, 2011, 16(1): 111-115.
[12]	王新, 杨玉雯, 王安才, 孔祥权. 缬沙坦干预对缺氧性肺动脉高压大鼠大电导钙激活钾通道的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 1032-1035.
[13]	吴军, 王良兴, 应斌宇, 施孟如. 葛根素干预肺动脉高压大鼠时钙网蛋白前体变化的研究[J]. 中国临床药理学与治疗学, 2009, 14(1): 14-19.
[14]	吴建华, 方云祥. 法舒地尔对大鼠脑缺血再灌注损伤炎症反应的影响[J]. 中国临床药理学与治疗学, 2008, 13(4): 377-383.
[15]	李娜, 王秋娟, 戴德哉, 贺海波, 冯瑜, 戴茵. 内皮素受体拮抗剂CPU0213 对博莱霉素及油酸的小鼠肺损伤及纤维化的改善作用[J]. 中国临床药理学与治疗学, 2007, 12(9): 998-1003.